MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (List of indian pharma Stocks)
- Indian Pharma Stocks
Indian Pharma
Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
New Research: Our #1 Stock Pick Right Now
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 817.85 2.59% | 817.50 2.41% |
|
More Info
|
| AJANTA PHARMA | 1,959.75 -2.16% | 1,961.25 -2.18% |
|
More Info
|
| ALEMBIC PHARMA | 938.55 -1.30% | 939.05 -1.27% |
|
More Info
|
| BIOCON | 388.95 0.92% | 388.80 0.87% |
|
More Info
|
| CADILA HEALTHCARE | 617.10 -4.61% | 617.15 -4.61% |
|
More Info
|
| CIPLA | 904.10 0.60% | 904.05 0.61% |
|
More Info
|
| DIVIS LABORATORIES | 4,022.00 -0.97% | 4,020.55 -1.01% |
|
More Info
|
| DR. REDDYS LAB | 5,195.85 -2.00% | 5,196.85 -1.97% |
|
More Info
|
| GLENMARK PHARMA | 607.85 -2.56% | 608.30 -2.48% |
|
More Info
|
| INDOCO REMEDIES | 353.55 0.47% | 354.60 0.74% |
|
More Info
|
| IPCA LABS | 2,148.35 0.55% | 2,148.85 -0.16% |
|
More Info
|
| J.B.CHEMICALS | 1,385.75 -0.07% | 1,385.15 -0.13% |
|
More Info
|
| LUPIN | 1,178.80 -2.64% | 1,178.45 -2.79% |
|
More Info
|
| NATCO PHARMA | 928.30 0.46% | 927.45 0.29% |
|
More Info
|
| NIFTY 50 | Not Listed | 14,677.80 -0.13% |
|
More Info
|
| ORCHID PHARMA | 1,421.75 -1.96% | 18.90 -2.83% |
|
More Info
|
| PANACEA BIOTECH | 380.50 1.41% | 379.95 1.10% |
|
More Info
|
| PIRAMAL ENTERPRISES | 1,633.00 -3.64% | 1,633.65 -3.61% |
|
More Info
|
| S&P BSE HEALTHCARE | 24,090.62 -1.20% | Not Listed |
|
More Info
|
| S&P BSE SENSEX | 48,732.55 0.09% | Not Listed |
|
More Info
|
| STRIDES PHARMA SCIENCE | 808.15 -0.19% | 808.35 -0.15% |
|
More Info
|
| SUN PHARMA | 691.10 -1.64% | 691.45 -1.62% |
|
More Info
|
| TORRENT PHARMA | 2,722.50 -0.12% | 2,722.30 -0.13% |
|
More Info
|
| WOCKHARDT | 632.25 0.29% | 633.80 0.47% |
|
More Info
|
BSE prices: May 14, 2021 (Close) NSE prices: May 14, 2021 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 13,885.5 (down 1.3%). The index is up 7.1% over the last 30 days. And over the last 1 year, it has gained 50.2%.
Within the Indian Pharma sector, the top gainers were AARTI DRUGS (up 2.6%) and PANACEA BIOTECH (up 1.4%). On the other hand, CADILA HEALTHCARE (down 4.6%) and PIRAMAL ENTERPRISES (down 3.6%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 14,677.8 (down 0.1%).
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views on News
Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)
May 14, 2021The company's board recommended a final dividend of Rs 25 for financial year 2020-21.
What's Behind the Rally in Pharma Stocks? (Views On News)
May 11, 2021The second wave of Covid has given a new lease of life to pharma stocks.
Why Did Alembic Pharma Shares Fall Today? (Views On News)
May 5, 2021Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.
DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMost Popular
Is Intraday Trading For You? (Fast Profits Daily)
May 13, 2021Do you think you have what it takes to be an intraday trader? Find out in this video.
My Secret to Find Breakthrough Stocks (Fast Profits Daily)
May 7, 2021I've used this trading technique for many years with great success. I'm sharing it with you today.
Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)
May 6, 2021Why are markets discounting the economic impact of Covid?
The Key to Profit from India's EV Revolution (Profit Hunter)
May 7, 2021Stocks you must consider investing in before buying your first electric vehicle.
MoreOUR TOP 5 IDEAS
- New Research: Our #1 Stock Pick Right Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
S&P BSE HEALTHCARE
May 14, 2021 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.